Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient

Most patients diagnosed with hepatocellular carcinoma (HCC) have advanced diseases, and many are not eligible for curative therapies. There is growing evidence suggesting that the combination treatment of PD-1/PD-L1 inhibitors and tyrosine kinase inhibitors (TKIs) is becoming a prospective trend for...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Er-lei, Zhang, Zun-yi, Li, Jian, Huang, Zhi-yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727032/
https://www.ncbi.nlm.nih.gov/pubmed/33311988
http://dx.doi.org/10.2147/OTT.S284092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727032/
https://www.ncbi.nlm.nih.gov/pubmed/33311988
http://dx.doi.org/10.2147/OTT.S284092

Ejemplares similares